SECUKINUMAB
secukinumab 150 mg/mL injection, 1 mL pen device
SECUKINUMAB (12297F)
12297F
Manner of administration:Injection
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a
break in biological medicine of less than 5 years) or Initial 3 (Recommencement of
treatment after a break in biological medicine of more than 5 years) - balance of
supply
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $676.80 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cosentyx | |||||